Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 8,279 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Leukemia
Interventions: filgrastim, asparaginase, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, mesna, methotrexate, methylprednisolone, pegaspargase, prednisone, therapeutic hydrocortisone, vincristine sulfate, allogeneic bone marrow transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 1 Year
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 30
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 24 more

Conditions: Multiple Myeloma
Interventions: Melphalan, Bortezomib; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 60 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Asthma, Obesity, ADHD
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 3 Years to 5 Years
Enrollment: 960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Plaque Psoriasis
Interventions: Zasocitinib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 11
States / cities: Chula Vista, California • Fountain Valley, California • Hialeah, Florida + 8 more

Conditions: Factor VIII Deficiency
Interventions: efanesoctocog alfa (BIVV001); Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 12 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Gainesville, Florida + 4 more

Conditions: Influenza
Interventions: Flucelvax® (ccIIV3), Flublok® (RIV3); Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 606 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 3 more

Conditions: Fatigue, Pain, Poor Sleep Quality
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Contraception
Interventions: Ulipristal Acetate, Combined Oral Contraceptive Pill; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Asthma
Interventions: Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 6
States / cities: Long Beach, California • Miami, Florida • Lafayette, Louisiana + 3 more

Conditions: Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Still Disease
Interventions: Local laboratory testing, Local Lab Tests; Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: Up to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 14 more

Conditions: Premature Birth, Bronchopulmonary Dysplasia, Asthma
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 2 Months to 36 Months
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Alzheimer Disease
Interventions: transcranial alternating current stimulation (tACS); Device
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 21 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gene Therapy, Hemophilia B
Interventions: Interview; Behavioral
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 12 Years and older
Enrollment: 150 participants
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Head and Neck Cancer
Interventions: Cetuximab, 50-60 Gy and 70 Gy; Drug · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 70 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Pediatric Obesity, Risk Reduction Behavior, Early Intervention, Intergenerational Relations
Interventions: Caregiver Component., Caregiver-Preschooler Learning., Center-based Preschooler Component.; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 3 Years to 5 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Influenza
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 11 Months
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 15
States / cities: Birmingham, Alabama • Pulaski, Arkansas • Orange, California + 12 more

Conditions: Healthy, Child Development
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Months to 45 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diphtheria, Tetanus, Acellular Pertussis
Interventions: Combined diphtheria, tetanus, acellular pertussis vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 4,116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 44
States / cities: Mesa, Arizona • Tempe, Arizona • Jonesboro, Arkansas + 39 more

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2025
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Invasive Fungal Infection
Interventions: Posaconazole IV 6 mg/kg, Posaconazole PFS 6 mg/kg; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Day to 2 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: San Diego, California • Miami, Florida • Chicago, Illinois + 2 more

Conditions: Secondary Hypogonadism
Interventions: Androxal 25 mg; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Miami, Florida • Minneapolis, Minnesota

Conditions: Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Interventions: Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: University of Washington; Other
Eligibility: 60 Years to 90 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: vepdegestrant, PF-07220060; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 22 more

Search by objective public record fields.

Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

HealthSpark: Health Access for Children in Federally-Subsidized Child Care

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

Immunogenicity of Influenza Vaccinations

Molecular Determinants of Persistent Cancer Related Fatigue

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma

Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant.

Assessment of Lung Structure and Function of Infants Born Prematurely

Memory Functions in Mild Alzheimer's Disease

Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy

Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)

FirstStep2Health Intervention

Chart Review of Antivirals for Influenza in Infants

Event Related Potentials in Infants and Adults

A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine

Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

A Long-term Extension Study of Ustekinumab in Pediatric Participants

Hormone and Information Processing Study

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.